Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204215 | 0.86 | — | — | |
| SCHEMBL63128 | 0.86 | — | — | |
| SCHEMBL18867939 | 0.86 | — | — | |
| SCHEMBL30437684 | 0.86 | — | — | |
| Formaldehyde SCHEMBL28836070 | 0.84 | MAOB (0.47) | MAOBALDH1A1CES2CES1RELA | |
| Fluoride SCHEMBL25408744 | 0.84 | MAOB (0.50) | MAOBALDH1A1CES2CES1RELA | |
| SCHEMBL1072810 | 0.84 | — | — | |
| Magnesium SCHEMBL29442861 | 0.84 | — | — | |
| SCHEMBL851628 | 0.84 | CES2 (0.46) | CA1CA2CA9CES2CES1 | |
| Fluoride SCHEMBL31239659 | 0.84 | MAOB (0.50) | MAOBALDH1A1CES2CES1RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608369-B | Sulfonyl ester group anthraquinone derivative and preparation method and application thereof | 广西大学 | 2021-04-09 | — | — | CN | claimed |
| CN-102603630-A | O-aminobenzoic acid sulfonylation derivative as well as preparation method and application thereof | UNIV BEIJING SCIENCE & TECH | 2012-07-25 | — | — | CN | claimed |
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-01-05 | — | — | US | disclosed |
| CN-106243037-A | The substituted phenylurea of part and phenyl amide as Rhizoma et radix valerianae compounds receptor | 格吕伦塔尔有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-101031564-A | Piperazine derivatives for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2007-09-05 | — | — | CN | disclosed |
| CN-101006092-A | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1906154-A | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1630642-A | Benzenesulfonamide derivatives | GLAXO GROUP LTD (GB) | 2005-06-22 | — | — | CN | disclosed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | disclosed |
| CN-1037568-C | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1998-03-04 | — | — | CN | disclosed |
| CN-1165144-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1165143-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1066266-A | PHOSPHOSULFONATE HERBICIDES | ROHM & HAAS (US) | 1992-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | MAOB 235/4885CA1 1161/4885CA2 678/4885 |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | MAOB 416/4885CA1 2195/4885CA2 1088/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | MAOB 416/4885CA1 2195/4885CA2 1088/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | MAOB 235/4885CA1 1161/4885CA2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.